U.S. Markets close in 4 hrs 3 mins

Cannabis and Biotech Stocks That Could Bounce

HENDERSON, NV / ACCESSWIRE / November 1, 2018 / A stem cell play we like a lot is BioRestorative Therapies, Inc.,(BRTX) a life sciences company focused on stem cell-based therapies. They recently reported the findings from Defined Health, which was engaged by BRTX to conduct an independent review of BRTX-100, the Company's lead cell therapy candidate designed to treat chronic Lumbar Disc Disease. Defined Health is a business development and strategy consulting firm that has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years.

BRTX plans to use the results of the review to further refine its planned activities around BRTX-100, including potential licensing, co-development and commercialization activities.

Since announcing this news, BRTX has seen increased interest from investors this summer, which may lead to a major move in the near future.

Prior to the commencement of their trial may be the ideal time to take a look at BRTX. BRTX also just had very positive news of an addition to their management team.

Companies to put on your radar include: BioRestorative Therapies, Inc. (BRTX), Cara Therapeutics Inc. (CARA), Charlotte's Web Holdings, Inc. (CWBHF), Aurora Cannabis, Inc. (ACB) and Aphria, Inc. (APHQF).

BioRestorative Therapies, Inc. (BRTX)

Market Cap: $10.14M Share Price: $1.1275

BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, announced the appointment of Lance Alstodt as Executive Vice President and Chief Strategy Officer. In this capacity, Mr. Alstodt will be responsible for developing and refining the Company's overall strategy and implementing investment decisions. Mr. Alstodt brings over 25 years of experience in operations, strategy and mergers & acquisitions.

Cara Therapeutics Inc. (CARA)

Market Cap: $832.96M, current share price: $21.20

Cara Therapeutics, Inc. is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute postoperative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan.

Charlotte's Web Holdings, Inc. (CWBHF)

Market Cap: $821.44M Share Price: $8.75

Charlotte's Web Holdings, Inc., the market share leader in hemp-based CBD wellness products, has surpassed 3000 retail locations across the United States. At the end of 2017, Charlotte's Web products were sold in approximately 2,000 locations. The Company disclosed today that it surpassed its 2018 year-end goal of 3,000 locations during the 3rd quarter.

Aurora Cannabis, Inc. (ACB)

Market Cap: $9.56B Share Price: $9.96

The company has begun trading on the NYSE, but the company's stock has been getting beat up. The company has reported that it has been granted the ability to ship cannabis to Poland, which is very favorable for the company and its shareholders. Watch for ACB to make a bounce in the company weeks.

Aphria, Inc. (APHQF)

Market Cap: $3.11B Share Price: $12.39

Aphria Inc. (APHQF) announced closing the acquisition of LATAM Holdings Inc. from Scythian Biosciences (SCCYF). The Transaction was funded by the assumption of US$1 million of existing LATAM Holdings debt with the remaining consideration funded by the issuance of 15,678,310 common shares of Aphria. The closing was pursuant to the terms of the definitive share purchase agreement previously announced by the Company on July 17, 2018.

Important Disclaimer, Please Read:

The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.

The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.

Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. BRTX has paid, and continues to pay Regal to disseminate truthful and potentially material information regarding BRTX.

Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.

Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.

Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in BRTX can be found updated here: http://www.regalconsultingllc.com/disclaimer/.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and twenty three thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of BRTX in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC,For Full Legal Disclaimer Click Here.

Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email:
info@microcapspecualtors.com
Phone:
1-702-720-6310
Country:
United States
Website:
http://microcapspeculators.com/

SOURCE: ACR Communication, LLC